Medi Caps Ltd
Incorporated in 1983, Medi-Caps Ltd is in the business of real estate and pharmaceuticals[1]
- Market Cap ₹ 54.6 Cr.
- Current Price ₹ 43.8
- High / Low ₹ 61.0 / 41.0
- Stock P/E 107
- Book Value ₹ 54.2
- Dividend Yield 0.00 %
- ROCE 7.34 %
- ROE 5.91 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 0.81 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 1.49% over last 3 years.
- Earnings include an other income of Rs.0.44 Cr.
- Company has high debtors of 237 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Realty Industry: Construction
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
26.03 | 27.37 | 27.37 | 25.04 | 22.76 | 26.38 | 25.28 | 10.91 | 0.00 | 0.00 | 0.10 | 7.17 | 3.50 | |
22.24 | 24.21 | 25.52 | 23.42 | 21.99 | 25.93 | 25.32 | 19.97 | 0.00 | 0.56 | 0.39 | 2.33 | 2.78 | |
Operating Profit | 3.79 | 3.16 | 1.85 | 1.62 | 0.77 | 0.45 | -0.04 | -9.06 | 0.00 | -0.56 | -0.29 | 4.84 | 0.72 |
OPM % | 14.56% | 11.55% | 6.76% | 6.47% | 3.38% | 1.71% | -0.16% | -83.04% | -290.00% | 67.50% | 20.57% | ||
-1.33 | -1.57 | 1.21 | 0.46 | 1.13 | 0.67 | 1.14 | 1.11 | -0.12 | 0.64 | 0.53 | 0.15 | 0.44 | |
Interest | 0.01 | 0.03 | 0.01 | 0.01 | 0.02 | 0.02 | 0.04 | 0.01 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
Depreciation | 0.63 | 0.34 | 0.32 | 0.33 | 0.37 | 0.34 | 0.35 | 0.36 | 0.00 | 0.09 | 0.09 | 0.16 | 0.16 |
Profit before tax | 1.82 | 1.22 | 2.73 | 1.74 | 1.51 | 0.76 | 0.71 | -8.32 | -0.12 | -0.02 | 0.15 | 4.83 | 1.00 |
Tax % | 63.19% | 89.34% | 29.30% | 32.18% | 23.18% | 26.32% | 16.90% | 0.12% | -8.33% | 50.00% | 0.00% | 19.46% | |
0.67 | 0.14 | 1.94 | 1.18 | 1.16 | 0.56 | 0.59 | -8.33 | -0.11 | -0.04 | 0.15 | 3.89 | 0.51 | |
EPS in Rs | 0.54 | 0.11 | 1.56 | 0.95 | 0.93 | 0.45 | 0.47 | -6.68 | -0.09 | -0.03 | 0.12 | 3.12 | 0.41 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | -13% |
5 Years: | -22% |
3 Years: | % |
TTM: | -33% |
Compounded Profit Growth | |
---|---|
10 Years: | 39% |
5 Years: | 57% |
3 Years: | 622% |
TTM: | -84% |
Stock Price CAGR | |
---|---|
10 Years: | 11% |
5 Years: | 32% |
3 Years: | -7% |
1 Year: | -16% |
Return on Equity | |
---|---|
10 Years: | 0% |
5 Years: | -2% |
3 Years: | 1% |
Last Year: | 6% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 |
Reserves | 49.81 | 49.95 | 51.89 | 53.07 | 53.90 | 54.45 | 55.04 | 47.38 | 48.50 | 48.82 | 48.64 | 54.02 | 55.07 |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.17 | 0.12 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
4.12 | 4.93 | 4.58 | 5.47 | 5.64 | 4.73 | 6.16 | 1.65 | 1.66 | 0.52 | 0.52 | 1.60 | 0.68 | |
Total Liabilities | 66.40 | 67.35 | 68.94 | 71.01 | 72.01 | 71.82 | 73.79 | 61.56 | 62.63 | 61.81 | 61.63 | 68.09 | 68.22 |
4.28 | 3.90 | 3.96 | 3.64 | 4.96 | 5.01 | 4.99 | 3.63 | 3.26 | 2.78 | 2.46 | 2.26 | 2.18 | |
CWIP | 0.00 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 33.75 | 41.75 | 48.25 | 49.56 | 49.29 | 49.81 | 50.67 | 52.15 | 54.39 | 53.68 | 51.98 | 55.11 | 56.85 |
28.37 | 21.60 | 16.73 | 17.81 | 17.76 | 17.00 | 18.13 | 5.78 | 4.98 | 5.35 | 7.19 | 10.72 | 9.19 | |
Total Assets | 66.40 | 67.35 | 68.94 | 71.01 | 72.01 | 71.82 | 73.79 | 61.56 | 62.63 | 61.81 | 61.63 | 68.09 | 68.22 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-7.99 | -1.57 | 6.88 | 1.44 | 2.70 | 0.86 | 1.33 | -0.92 | 2.24 | -0.95 | -2.60 | 3.09 | |
7.27 | 1.61 | -6.78 | -1.31 | -1.76 | -0.96 | -1.19 | -0.40 | -2.19 | 1.01 | 1.85 | -3.09 | |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.17 | -0.05 | -0.06 | -0.06 | 0.00 | 0.00 | 0.00 | |
Net Cash Flow | -0.72 | 0.04 | 0.10 | 0.13 | 0.94 | 0.07 | 0.09 | -1.38 | -0.02 | 0.06 | -0.75 | 0.00 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 94.65 | 106.69 | 88.55 | 96.35 | 97.18 | 96.02 | 90.24 | 88.99 | 8,176.00 | 236.72 | ||
Inventory Days | 156.54 | 169.28 | 194.04 | 248.47 | 281.91 | 219.00 | 266.47 | 20.89 | 1,825.00 | |||
Days Payable | 20.09 | 36.41 | 33.53 | 60.03 | 83.09 | 55.89 | 118.09 | 16.56 | 1,095.00 | |||
Cash Conversion Cycle | 231.10 | 239.55 | 249.06 | 284.79 | 296.00 | 259.13 | 238.62 | 93.33 | 8,176.00 | 236.72 | ||
Working Capital Days | 265.30 | 153.09 | 158.96 | 175.94 | 179.45 | 157.59 | 160.12 | 133.82 | 25,623.00 | 481.07 | ||
ROCE % | 6.18% | 1.94% | 4.29% | 2.69% | 1.52% | 1.14% | 0.77% | -13.56% | 0.00% | -0.85% | -0.62% | 7.34% |
Documents
Announcements
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
17 Apr - Declaration of non-applicability as Large Corporate under SEBI circular.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
4 Apr - Certificate for compliance of Regulation 74(5) of SEBI(DP) Regulation 2018 for the quarter ended 31.03.2025
-
Closure of Trading Window
26 Mar - Closure of trading window from April 1, 2025.
-
Intimation Under Regulation 30 For Inspection Of U.S. FDA Of Wholly Owned Subsidiary
24 Feb - USFDA inspection issued Form 483 with procedural observations.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
14 Feb - Extract of un-audited standalone and consolidated financial results of the company for the quarter and nine months ended on 31.12.2024 published in Free Press English …
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
MCL operates in real estate as a parent company and pharma division through its wholly owned subsidiary. The company entered the real estate segment for city centric developments by way of Land acquisition and developing premium residential and commercial properties. It has almost completed its first project Medicaps Business Park and also sold ~50% of shops in the project